Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
MWN-AI** Summary
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that its abstract detailing the Phase 2 ALXN1840-WD-204 copper balance study has been accepted for oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025. The event is scheduled for November 7-11, 2025, in Washington, D.C., and Monopar's presentation is set for Sunday, November 9, from 9:00 to 9:15 am EST. The presentation will be led by Dr. Aftab Ala and focuses on the title, "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline."
Monopar is advancing its innovative treatments aimed at addressing unmet medical needs, with a primary focus on ALXN1840, which targets Wilson disease—a genetic disorder that leads to excessive copper accumulation in the body, potentially damaging organs. In addition to their lead product, Monopar is developing various radiopharmaceutical programs, including those aimed at imaging and treating advanced cancers.
The company emphasizes that the oral presentation's findings will be available on their website on November 9, and related materials can also be found on the AASLD conference website. Monopar's accomplishments reflect its commitment to addressing critical health challenges through innovative solutions.
However, forward-looking statements issued by the company highlight the inherent risks and uncertainties in the biopharmaceutical development process, including regulatory approvals and market acceptance. Monopar continues to navigate these challenges while focusing on advancing its pipeline and expanding its impact within the therapeutic landscape. For further information, stakeholders can connect with Monopar's investor relations or follow their social media updates.
MWN-AI** Analysis
Monopar Therapeutics Inc. (Nasdaq: MNPR) has generated notable market interest following the announcement of its abstract acceptance for an oral presentation at the 2025 AASLD – The Liver Meeting. This selection highlights the company's ongoing commitment to research and development, specifically its lead candidate, ALXN1840, aimed at treating Wilson Disease through improved copper balance. The oral presentation scheduled for November 9, 2025, represents not just a validation of the company’s research but also an opportunity to build momentum heading into regulatory discussions.
Investors should consider the implications of this presentation, as it could serve as a pivotal point for Monopar. The visibility from the conference provides an avenue for heightened engagement with potential investors, partners, and the medical community, particularly as it pertains to ALXN1840's efficacy in managing a condition with unmet medical needs.
However, it is essential to keep in mind the inherent risks highlighted by the company, particularly regarding regulatory approval and market acceptance of its products. The volatility characteristic of clinical-stage biopharmaceutical companies means investors should remain cautious. Monopar's ability to secure additional funding for continued development and to withstand pressures from competitors could significantly impact its short- and long-term performance.
Monitoring the outcomes of the presentation and subsequent clinical developments will be vital. Market sentiment can be influenced by the responses from the medical community and peers at the AASLD. Investors should watch for any partnership announcements or data on clinical trial results in the weeks following the presentation, as these could act as crucial catalysts that may drive MNPR’s stock price. Overall, while Monopar presents opportunity, diligence and risk assessment are paramount before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® 2025, taking place in Washington, D.C., from November 7-11, 2025.
Presentation Details:
- Title: Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline
- Publication Number: 0073
- Session: Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology
- Date: Sunday, November 9, 9:00-9:15 am EST
- Presenting Author: Aftab Ala, MBBS, M.D., FRCP, Ph.D.
The abstract is currently available on the conference website , and the materials for the oral presentation will be available at www.monopartx.com on November 9, 2025.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com
Follow Monopar on social media for updates:
X: @MonoparTx? LinkedIn: Monopar Therapeutics
FAQ**
What specific advancements or findings regarding Wilson Disease does the oral presentation from Monopar Therapeutics Inc. (MNPR) on November 9, 2025, aim to highlight during the AASLD conference?
How does Monopar Therapeutics Inc. (MNPR) plan to address the potential risks and uncertainties related to the regulatory approval process for ALXN1840 as indicated in their forward-looking statements?
In what ways could the outcomes of the Phase 2 ALXN1840-WD-204 study impact Monopar Therapeutics Inc.'s (MNPR) market position and strategic goals in the biopharmaceutical industry?
What funding strategies is Monopar Therapeutics Inc. (MNPR) considering to support the commercial development of their product candidates, particularly in light of the financial challenges mentioned in their recent statements?
**MWN-AI FAQ is based on asking OpenAI questions about Monopar Therapeutics Inc. (NASDAQ: MNPR).
NASDAQ: MNPR
MNPR Trading
-1.36% G/L:
$57.825 Last:
48,493 Volume:
$57.76 Open:
